Caricamento azienda
Keep exploring
The themes Vertex Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,5B USDA+
EXELExelixis, Inc.17B USDA+
JAZZJazz Pharmaceuticals plc15,4B USDA
HALOHalozyme Therapeutics, Inc.11,5B USDA+
TECHBIO-Techne Corp11,4B USDA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 ott 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 ott 2026BAGraded B, now A
Come guadagna
- TRIKAFTA/KAFTRIO sales75%
- ALYFTREK sales17%
- KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI sales4%
- CASGEVY sales2%
- JOURNAVX sales2%
Le quote di ricavo sono stime per quarter ended June 30, 2026, non cifre tratte da un documento depositato.
Compete con
Che cosa vende5
ALYFTREK
A once-daily combination medicine that improves the function of the faulty protein that causes cystic fibrosis.
TRIKAFTA/KAFTRIO
A combination medicine that improves the function of the faulty protein that causes cystic fibrosis. TRIKAFTA and KAFTRIO are brand names used in different markets.
KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI
Other medicines for cystic fibrosis that improve the function of the protein involved in the disease.
Mostra altri 2
CASGEVY
A gene-editing treatment for severe sickle cell disease and transfusion-dependent beta thalassemia. A patient's blood-forming cells are collected, edited at a manufacturing facility, and returned for infusion.
JOURNAVX
An oral, non-opioid medicine for moderate-to-severe acute pain in adults.
Chi lo compra5
- Specialty pharmacies and specialist distributors buy Vertex medicines and resell them to patients, pharmacies, health care providers, hospitals, or treatment centers.
- Major wholesalers in the United States buy Vertex medicines for resale through pharmacies and health care providers.
- Outside the United States, distributors, retail pharmacies, hospitals, and clinics buy or distribute medicines; some hospitals and clinics are government-owned or supported.
Mostra altri 2
- Authorized treatment centers can receive CASGEVY directly from Vertex in some markets.
- Government health programs and commercial insurers decide whether to cover medicines and reimburse purchases.
Su cosa si regge e cosa potrebbe romperlo
Da che cosa dipende l'attività
- 1The business depends substantially on cystic fibrosis medicines; sales therefore depend on continued patient use, access, and the medicines' ability to compete with other treatments.
- 2Vertex relies on outside manufacturers and suppliers for much of its commercial and clinical supply. CASGEVY also requires coordinated cell collection, editing, shipping, and treatment-center infusion.
- 3Sales depend on government programs and commercial insurers covering medicines and agreeing to reimbursement terms. The company also pays royalties on certain cystic fibrosis medicines and shares CASGEVY profits with CRISPR Therapeutics.
Che cosa potrebbe andare storto
- 1The company identifies its cystic fibrosis medicines as a substantial source of business dependence. Competing treatments, changes in patient use, or loss of patent protection could reduce sales.
- 2Vertex's future products depend on clinical trials showing acceptable safety and benefit and on regulators approving them. A delay or failure in programs such as povetacicept, inaxaplin, or zimislecel could limit its ability to add new medicines.
- 3The company relies on complex supply chains, outside manufacturers, and treatment-center coordination, particularly for cell and gene therapies. Manufacturing or distribution problems could delay or interrupt supply.
Informazioni su Vertex Pharmaceuticals Inc.
Vertex discovers, tests, manufactures, and sells prescription medicines. Its approved medicines treat cystic fibrosis, severe sickle cell disease, transfusion-dependent beta thalassemia, and moderate-to-severe acute pain; it is also testing treatments for kidney disease, type 1 diabetes, and other conditions. It sells mainly through specialty pharmacies, distributors, and wholesalers, with some gene therapy supplied directly to treatment centers.
- Sede
- Boston, Massachusetts
- Fondata nel
- 1989
- Dipendenti
- 6,400 (December 31, 2025, high)
- Quotata su
- NASDAQ
- Chiusura dell'esercizio
- December 31
Costruito dai documenti depositati da Vertex Pharmaceuticals Inc. presso la Securities and Exchange Commission (SEC), l’autorità di vigilanza statunitense. Le cifre sono quelle dichiarate, con lo storico per azione ricalcolato sulla base azionaria di oggi. Questo descrive un’azienda: non è consulenza finanziaria né una raccomandazione di acquisto o vendita.